YOUR INVITATION TO JOIN US!

45 MINUTE PRESENTATION
PLUS 15 MINUTES QUESTION TIME

SUPPORTING MENTAL HEALTH TREATMENT IN PRIMARY CARE

Dr Kripa Chakravarthy & Dr Pramod Menon

START TIME: 06:30 pm FINISH TIME: 08:30 pm DATE: Wednesday 26th May 2021

VENUE: The Empire Hotel, 5 East Street, Rockhampton

START
6.30 pm Registration
7 pm Meeting start

→ **WELCOME** → **PRESENTATION** → **Q&A** → **CLOSE**
8.30 pm

ABOUT THE SPEAKER

Dr Kripa Chakravarthy, Consultant Psychiatrist, Acute Care Team & CL Team, Rockhampton Base will present on:
- The Acute Care Team & Mental Health Referrals &
- The Management of Psychiatric Disorders in General Practise

Dr Pramod Menon, Consultant Psychiatrist in private practise at Hillcrest Rockhampton Private will present on:
- The Management of Depression in Primary Care, the role of Brintellix (vortioxetine) in treating MDD

REGISTER

Places are limited. RSVP to your representative to avoid disappointment.

Contact details:

Name: Fiona Hart

Phone: 0490 857 506

Email: fiona.hart@hahnmentalhealthcare.com.au

RSVP BY: Friday, 21st May 2021

PARKING INSTRUCTIONS

Street parking

Brintellix® vortioxetine

For the treatment of major depressive disorder in adults including prevention of relapse.[1]

Hahn Healthcare
ON BEHALF OF LUNDBECK & OTSUKA

FURTHER DETAILS

Inclusions: This invitation is for the intended recipient and applicable only for the venue to which they were invited to attend. Lundbeck Australia is not able to provide transport or accommodation associated with this event. As part of the sponsorship we anticipate that you will attend the educational session at the meeting. All attendees are responsible for obtaining approval to receive and/or disclose hospitality as required by their employers or professional association. Lundbeck Australia will not subsidise or pay for the hospitality, travel or other expenses of any guest, family, companion or any other person associated with a delegate attending an educational event.

CPD Points: This is not an accredited educational activity. Healthcare professionals can self-record their participation and claim CPD/CME points as a self-directed non-accredited activity.

Lundbeck privacy statement: Your privacy is important. In your interactions with Lundbeck, we may collect personal information including your name and contact details and use it to assist healthcare professionals to seek to improve healthcare and patient satisfaction, as well as to improve our services. For further information, please see "Lundbeck and Privacy" on our website at www.lundbeck.com/au

PBS Information: This product is not listed on the PBS.

Please review Brintellix Approved Product Information before prescribing.
Product Information is available by calling Lundbeck on 1300 721 277.

Minimum Product Information: Brintellix® (vortioxetine hydrobromide). **Pharmacology:** BRINTELLIX has multimodal activity, which is a combination of two pharmacological modes of action: direct modulation of serotonin receptor activity and inhibition of the serotonin transporter. Nonclinical data suggest that this leads to modulation of neurotransmission in several systems, including serotonin, norepinephrine, dopamine, histamine, acetylcholine, GABA and glutamate systems. **Indications:** Treatment of major depressive disorder in adults including prevention of relapse. Vortioxetine is not indicated for paediatric use. **Dosage & Administration:** To be taken with or without food. Adults: 10 mg once daily; depending on individual response maximum 20 mg once daily or reduced to 5 mg once daily. Elderly (≥65 years): 5 mg once daily; increase to 10 mg once daily if required. Dosage adjustment may be required for strong CYP2D6 inhibitors or CYP450 inducers. Treatment for at least 6 months is recommended for consolidation of response. **Contraindications:** Hypersensitivity to any component of BRINTELLIX. Concomitant treatment with MAOIs or treatment within 14 days of MAOIs. **Precautions:** Clinical worsening and suicide risk; Neuroleptic Malignant Syndrome; Serotonin Syndrome; activation of mania/hypomania; seizures; haemorrhage; hyponatraemia; severe hepatic impairment; severe renal impairment; raised intraocular pressure; angle-closure glaucoma; pregnancy (Category B3); electroconvulsive therapy; breastfeeding is not recommended. **Interactions:** MAOIs (see full PI for details); serotonergic medicines including tramadol and triptans; St John's Wort; Cytochrome P450 inducers e.g. rifampicin; Cytochrome P450 inhibitors e.g. bupropion; antiplatelets; anticoagulants; lithium; tryptophan; medicines lowering the seizure threshold including SSRIs, SNRIs, tricyclics, neuroleptics, mefloquine, tramadol. **Adverse Effects:** nausea; vomiting; diarrhoea; constipation; decreased appetite; sedation; generalised pruritus; *hyponatraemia**. For all other adverse events see full PI.
Date of TGA approval: 31 March 2014. **Date of TGA update:** 21 September 2020. **Date of Minimum PI:** 12 Nov 2020
*Please note changes to minimum product information in italics

1. Brintellix® Australian Approved Product Information.

Lundbeck Australia Pty Ltd, ABN 86 070 094 290. Ground Floor, 1 Innovation Road, North Ryde NSW 2113
Ph: +61 2 8669 1000, Fax: +61 2 8669 1090, Medical Information: 1300 721 277
Otsuka Australia Pharmaceutical Pty Ltd, ABN 20 601 768 754, Chatswood NSW 2067
Prepared January 2021. AU-BRIN-0261

Form is read-only if ticked: ☑